Celularity Ownership
| CELU Stock | USD 2.01 0.84 29.47% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 17.8 M | Current Value 21.8 M | Avarage Shares Outstanding 64.3 M | Quarterly Volatility 58.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Celularity |
Celularity Stock Ownership Analysis
About 50.0% of the company shares are held by company insiders. The book value of Celularity was currently reported as 1.27. The company recorded a loss per share of 104.78. Celularity had not issued any dividends in recent years. The entity had 1:10 split on the 29th of February 2024. Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. Celularity operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people. For more info on Celularity please contact Robert MD at 908 768 2170 or go to https://www.celularity.com.Besides selling stocks to institutional investors, Celularity also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Celularity's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Celularity's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Celularity Quarterly Liabilities And Stockholders Equity |
|
Celularity Insider Trades History
About 50.0% of Celularity are currently held by insiders. Unlike Celularity's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Celularity's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Celularity's insider trades
Celularity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Celularity is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Celularity backward and forwards among themselves. Celularity's institutional investor refers to the entity that pools money to purchase Celularity's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Simplex Trading, Llc | 2024-06-30 | 5.4 K | Bank Of America Corp | 2024-06-30 | 2.3 K | Tower Research Capital Llc | 2024-06-30 | 2 K | Ubs Group Ag | 2024-06-30 | 1.2 K | Ifp Advisors, Llc | 2024-06-30 | 1000 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 700 | Global Retirement Partners, Llc. | 2024-09-30 | 300 | Weaver Capital Management, Llc | 2024-09-30 | 300 | Rhumbline Advisers | 2024-06-30 | 189 | Vanguard Group Inc | 2024-09-30 | 500.1 K | Geode Capital Management, Llc | 2024-09-30 | 137.5 K |
Celularity Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celularity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celularity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celularity insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Celularity Outstanding Bonds
Celularity issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Celularity uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Celularity bonds can be classified according to their maturity, which is the date when Celularity has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Celularity Corporate Filings
| 19th of November 2024 Other Reports | ViewVerify | |
| 15th of November 2024 Other Reports | ViewVerify | |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.